Overall, our research highlights the therapeutic value of targeting RPA and metabolic pathways in NPC, providing a promising avenue for improving treatment outcomes and potentially overcoming the challenging treatment resistance of NPC to radiotherapy. The gene discussed is RPA1; the disease is nasopharyngeal carcinoma.